A previous study has shown that the NAMPT inhibitor FK866 reduces mucosal NAD+ levels and the activation of NF‐κB, then ameliorates DSS‐induced colitis.[14] Moreover, clinical trials have been performed in advanced solid tumor malignancies to determine the toxicity profile and pharmacokinetics of FK866.[56] However, it is unclear whether FK866 can alleviate the resistance of UC patients to IFX. Here, NFKB1 is linked to colitis.